Angioplasty or medical therapy in patients with documented ischemia

Original title: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. Reference: Stergiopoulos K el al. JAMA Intern Med 2013; DOI:10.1001/jamainternmed.2013

The amount in ischemic patients with stable coronary heart disease is associated with poor prognosis. However, it is unclear whether revascularization to reduce that amount also reduces ischemic events compared with medical treatment.

This meta- analysis included major works that randomized patients with stable coronary artery disease and demonstrated ischemia  to revascularization or medical treatment (MASS II , COURAGE , BARI 2D , FAME 2, etc.) . A total of 4064 patients, all with documented ischemia by stress test, gamma camera, echo stress or fractional flow reserve were analyzed. The endpoints included in the analysis were death from any cause, nonfatal myocardial infarction, urgent revascularization and angina. With a median follow-up of 5 years,  mortality rate from all causes was observed in the group receiving revascularization by angioplasty  versus  those who only received medical treatment  6.5 % and 7.3 % respectively (OR 0.90 CI 95% 0.71 to 1.16; p= ns) , nonfatal myocardial infarction 9.2 % and 7.6% (OR 1.24 CI 95% 0.99 to 1.56; p=ns) , urgent revascularization 18.3 % and  28.4 % (OR 0.64, CI 95% 0.35 to 1.17) and angina 20.3 % and 23.3 % (OR 0.91, CI 95% 0.57 to 1.44).

Conclusion:

In patients with stable coronary artery disease and documented ischemia, percutaneous revascularization does not seem to reduce events compared with medical treatment alone.

Editorial comment

This work, like all meta-analyzes, drag the limitations of the studies in which it was based. For example, ischemia was documented in all patients but as a binary variable. If we know that the greater ischemia increased mortality, why not also expect a different benefit with revascularization according to the amount. The same should be considered for symptoms; to worse major functional class a greater relief should be by revascularization. Finally the localization of the ischemic territory is taken into account in daily practice but has been difficult to differentiate in the works and should be taken into consideration. Perhaps some of these questions can be answered by the 8000 patients that ISCHEMIA study plans to include. 

SOLACI.ORG

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...